Media Thread, page-5907

The company even went out of its way to inform shareholders 2.5 weeks ago that the current SP is not indicative of what the company is really worth.

In reality, things have only improved from our share price peak last year. Allow us to remind you about the company you are a shareholder in. Imugene is as strong as it has ever been as we continue to make good progress.

• We have $100 million in cash making us one of the most financially secure biotechs on the ASX

• We have 3 unique platform technologies supporting 6 unique assets – onCARlytics, CHECKvacc;

  PD1-Vaxx; CF33 (VAXINIA) & HER-Vaxx

• Within 12 months we expect to have ~10 clinical studies supported by 5-6 FDA IND’s

• Our drugs are targeting more than 10 disease areas

• We have 2 supply agreements with leading pharmaceutical companies

• We have 2 industry/scientific collaborations

  The balance of this year has some exciting developments expected for us:

• HER-Vaxx combination in two Phase 2 studies; one with BAVENCIO® (avelumab) and the other with KEYTRUDA® (pembrolizumab) in gastric cancer to commence dosing patients

• Final read out of the HERIZON HER-Vaxx study

• Trial of PD1-Vaxx in combination with TECENTRIQ® (atezolizumab) in lung cancer

• CHECKvacc already in cohort 2 with some interesting data as early as cohort 1

• VAXINIA oncolytic virus commenced dosing in patients

• onCARlytics, our oncolytic virus that expresses CD19, awaiting publication on the combination

  with Celularity and Eureka CAR T therapeutics

  Imugene is in immune-oncology therapies with a rich pipeline and prospects. We are financially secure and will continue to thrive.

IMU will be back at last year's peak ... of that I have no doubt. One hint CF33 preliminary results are looking positive will really start the snowball rolling.